Top Page
Basilea Pharmaceutica
(BSLN)
Basilea Pharmaceutica (BSLN) vs. iShares MSCI Switzerland ETF (EWL)
Basilea Pharmaceutica Business Overview & Revenue Model
Basilea Pharmaceutica Earnings Call Summary
Basilea Pharmaceutica Financial Statement Overview
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 184.23M | 208.54M | 157.63M | 147.76M | 148.12M | 127.63M |
| Gross Profit | 88.86M | 169.86M | 130.84M | 120.96M | 124.05M | 103.58M |
| EBITDA | 65.53M | 63.13M | 23.18M | 26.21M | 6.72M | -2.24M |
| Net Income | 64.76M | 77.59M | 10.45M | 12.15M | -6.83M | -14.72M |
Balance Sheet | ||||||
| Total Assets | 248.85M | 257.76M | 173.29M | 220.85M | 247.27M | 229.79M |
| Cash, Cash Equivalents and Short-Term Investments | 128.37M | 120.71M | 59.90M | 84.70M | 148.70M | 167.28M |
| Total Debt | 96.79M | 111.67M | 128.61M | 187.14M | 218.96M | 242.32M |
| Total Liabilities | 145.69M | 176.76M | 183.29M | 241.56M | 305.87M | 331.84M |
| Stockholders Equity | 103.16M | 81.00M | -10.00M | -20.71M | -58.61M | -102.05M |
Cash Flow | ||||||
| Free Cash Flow | 66.57M | 72.65M | 13.21M | 3.75M | -32.88M | -56.40M |
| Operating Cash Flow | 67.97M | 74.36M | 14.24M | 7.06M | -32.02M | -54.13M |
| Investing Cash Flow | -1.69M | -1.01M | -1.03M | 91.65M | 3.58M | -34.96M |
| Financing Cash Flow | -14.49M | -13.16M | -57.30M | -45.25M | 16.64M | 45.07M |
Basilea Pharmaceutica Technical Analysis
Basilea Pharmaceutica Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| ― | CHF561.52M | 7.82 | ― | ― | 58.51% | ― | |
| ― | $285.04M | 11.92 | ― | ― | 744.64% | ― | |
| ― | $1.10B | -183.95 | -7.82% | ― | 104.01% | 33.25% | |
| ― | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
| ― | CHF119.11M | -1.64 | -48.90% | ― | -91.34% | -2.84% | |
| ― | $140.58M | 2.58 | -301.13% | ― | -56.85% | -186.55% | |
| ― | CHF838.81M | -4.62 | ― | ― | 67.18% | -480.10% |
Basilea Pharmaceutica Corporate Events
Basilea Pharmaceutica AG announced that it has secured non-dilutive financial support from the Biomedical Advanced Research and Development Authority (BARDA) for the development of its novel oral antibiotic, Ceftibuten-Ledaborbactam Etzadroxil. This funding, which includes an initial USD 6 million and potential additional funding up to USD 153 million, will support the drug’s development for treating complicated urinary tract infections caused by multi-resistant bacteria, enhancing Basilea’s position in the anti-infective market.
The most recent analyst rating on (CH:BSLN) stock is a Buy with a CHF105.00 price target. To see the full list of analyst forecasts on Basilea Pharmaceutica stock, see the CH:BSLN Stock Forecast page.
Basilea Pharmaceutica announced that the US Biomedical Advanced Research and Development Authority (BARDA) has approved an additional $25 million funding for the development of its antifungal agents, Fosmanogepix and BAL2062. This funding supports ongoing Phase 3 studies and could significantly impact the company’s operations by advancing its drug development pipeline, potentially enhancing its market position in the treatment of life-threatening fungal infections.
The most recent analyst rating on (CH:BSLN) stock is a Buy with a CHF69.00 price target. To see the full list of analyst forecasts on Basilea Pharmaceutica stock, see the CH:BSLN Stock Forecast page.
Basilea Pharmaceutica is conducting a Phase 3 clinical study titled An Interventional Efficacy and Safety Phase 3 Double-blind 2-arm Study to Investigate IV Followed by Oral Fosmanogepix Compared With IV Caspofungin Followed by Oral Fluconazole in Adult Participants With Candidemia and/or Invasive Candidiasis. The study aims to evaluate the safety and efficacy of Fosmanogepix in treating candidemia and invasive candidiasis, serious fungal infections caused by Candida species. This research is significant as it seeks to demonstrate that Fosmanogepix is not inferior to the existing treatment regimen of caspofungin followed by fluconazole.
Basilea Pharmaceutica’s recent earnings call painted a picture of robust sales performance and strategic milestones, such as the successful U.S. launch of Zevtera and securing significant funding. However, the company faces challenges with decreased net profit due to past tax benefits, rising operating expenses, and an anticipated decline in product revenue from reduced supply to Pfizer. Overall, the sentiment remains positive, albeit with caution due to financial pressures.
Basilea Pharmaceutica is conducting a Phase 3 clinical study titled ‘An Interventional Phase 3, Open-label, Two-cohort Study to Investigate the Efficacy and Safety of Fosmanogepix in Adult Patients With Invasive Mold Infections.’ The study aims to evaluate the efficacy and safety of fosmanogepix in treating adult patients with invasive mold infections, a serious condition caused by various multidrug-resistant molds. This study holds significant potential in addressing unmet medical needs in antifungal treatments.
Basilea Pharmaceutica reported a significant financial performance in the first half of 2025, with a 36% increase in total revenue to CHF 104 million and a 160% rise in operating profit to CHF 24 million. The company achieved key milestones, including the launch of Zevtera in the US and the start of a Phase 3 study for Fosmanogepix, bolstering its market position and future growth prospects. The financial results underscore Basilea’s robust business model, enabling continued investment in its innovative clinical pipeline.
The most recent analyst rating on (CH:BSLN) stock is a Buy with a CHF95.00 price target. To see the full list of analyst forecasts on Basilea Pharmaceutica stock, see the CH:BSLN Stock Forecast page.
Study Overview: Basilea Pharmaceutica is conducting a Phase 3 clinical trial titled An Interventional Efficacy and Safety Phase 3 Double-blind 2-arm Study to Investigate IV Followed by Oral Fosmanogepix Compared With IV Caspofungin Followed by Oral Fluconazole in Adult Participants With Candidemia and/or Invasive Candidiasis. The study aims to evaluate the safety and efficacy of Fosmanogepix in treating life-threatening fungal infections caused by Candida species, with the primary goal of demonstrating that Fosmanogepix is not inferior to the standard treatment.
Basilea Pharmaceutica has entered into an exclusive license agreement with Venatorx Pharmaceuticals to acquire worldwide rights to Ceftibuten-Ledaborbactam Etzadroxil, an oral antibiotic combination targeting complicated urinary tract infections (cUTI). This agreement is expected to enhance Basilea’s product pipeline and support its strategy for sustainable revenue growth by addressing the significant need for effective oral treatments for cUTI caused by multi-resistant bacteria. The transaction involves upfront and milestone payments, with potential royalties for Venatorx, and is projected to increase Basilea’s R&D expenses by CHF 15 million in 2025.
The most recent analyst rating on (CH:BSLN) stock is a Buy with a CHF95.00 price target. To see the full list of analyst forecasts on Basilea Pharmaceutica stock, see the CH:BSLN Stock Forecast page.
Study Overview: Basilea Pharmaceutica is conducting a Phase 3 clinical study titled An Interventional Efficacy and Safety Phase 3 Double-blind 2-arm Study to Investigate IV Followed by Oral Fosmanogepix Compared With IV Caspofungin Followed by Oral Fluconazole in Adult Participants With Candidemia and/or Invasive Candidiasis. The study aims to evaluate the safety and efficacy of Fosmanogepix as a treatment for candidemia and invasive candidiasis, serious fungal infections. This study is significant as it seeks to establish Fosmanogepix as a potentially effective alternative to existing treatments.
Study Overview: Basilea Pharmaceutica is conducting a Phase 3 study titled An Interventional Phase 3, Open-label, Two-cohort Study to Investigate the Efficacy and Safety of Fosmanogepix in Adult Patients With Invasive Mold Infections. The study aims to evaluate the efficacy and safety of fosmanogepix in treating invasive mold infections, a significant concern due to the severity and resistance of these infections.
Study Overview: Basilea Pharmaceutica has completed a Phase 1 clinical study titled A Phase 1, Randomized, Single-center, Double-blind, Placebo-controlled Study of Fosmanogepix Administered as Single and Multiple Doses in Healthy Adult Chinese Subjects. The study aimed to investigate the pharmacokinetics and safety of fosmanogepix, an investigational drug, in healthy Chinese adults. This research is significant as it contributes to understanding the drug’s behavior in the body and its safety profile.
Study Overview: Basilea Pharmaceutica is conducting a Phase 3 study titled ‘An Interventional Phase 3, Open-label, Two-cohort Study to Investigate the Efficacy and Safety of Fosmanogepix in Adult Patients With Invasive Mold Infections.’ The study aims to evaluate the efficacy and safety of fosmanogepix for treating invasive mold infections, a significant concern due to the rising cases of multidrug-resistant molds.
Study Overview: Basilea Pharmaceutica is conducting a Phase 3 study titled An Interventional Phase 3, Open-label, Two-cohort Study to Investigate the Efficacy and Safety of Fosmanogepix in Adult Patients With Invasive Mold Infections. The study aims to evaluate the efficacy and safety of fosmanogepix for treating invasive mold infections in adults, focusing on reducing all-cause mortality by Day 42. This research is significant due to the increasing threat of multidrug-resistant molds.
Study Overview: Basilea Pharmaceutica is conducting a Phase 3 study titled ‘An Interventional Phase 3, Open-label, Two-cohort Study to Investigate the Efficacy and Safety of Fosmanogepix in Adult Patients With Invasive Mold Infections.’ The study aims to evaluate the efficacy and safety of fosmanogepix in treating invasive mold infections, a significant health concern due to its high mortality rate and limited treatment options.